company background image
J7Z logo

Jazz Pharmaceuticals DB:J7Z Stock Report

Last Price

€113.65

Market Cap

€7.0b

7D

4.3%

1Y

-12.1%

Updated

24 Mar, 2024

Data

Company Financials +

J7Z Stock Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.

J7Z fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance1/6
Financial Health1/6
Dividends0/6

Jazz Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jazz Pharmaceuticals
Historical stock prices
Current Share PriceUS$113.65
52 Week HighUS$135.05
52 Week LowUS$101.30
Beta0.59
1 Month Change-5.84%
3 Month Change4.46%
1 Year Change-12.06%
3 Year Change-19.96%
5 Year Change-10.51%
Change since IPO782.38%

Recent News & Updates

Recent updates

Shareholder Returns

J7ZDE PharmaceuticalsDE Market
7D4.3%2.6%1.4%
1Y-12.1%-24.2%7.5%

Return vs Industry: J7Z exceeded the German Pharmaceuticals industry which returned -24.2% over the past year.

Return vs Market: J7Z underperformed the German Market which returned 7.5% over the past year.

Price Volatility

Is J7Z's price volatile compared to industry and market?
J7Z volatility
J7Z Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: J7Z has not had significant price volatility in the past 3 months.

Volatility Over Time: J7Z's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20032,800Bruce Cozaddhttps://www.jazzpharma.com

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.

Jazz Pharmaceuticals plc Fundamentals Summary

How do Jazz Pharmaceuticals's earnings and revenue compare to its market cap?
J7Z fundamental statistics
Market cap€7.03b
Earnings (TTM)€383.89m
Revenue (TTM)€3.55b

18.3x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
J7Z income statement (TTM)
RevenueUS$3.83b
Cost of RevenueUS$284.13m
Gross ProfitUS$3.55b
Other ExpensesUS$3.14b
EarningsUS$414.83m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)6.65
Gross Margin92.59%
Net Profit Margin10.82%
Debt/Equity Ratio153.0%

How did J7Z perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.